Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Keating

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
Leukemia|May 19, 2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsNitin Jain, Philip Thompson, Jan Burger, et al.
Archives of Suicide Research : Official Journal of the International Academy for Suicide Research|June 26, 2026
Evaluation of the Overwatch Project for Active-Duty Servicemembers: Suicide Prevention with a Peer-Based Firearms Lethal Means Safety Training ApproachElisa Borah, Joseph C Geraci, Chris M Paine, et al.
NPJ Precision Oncology|November 4, 2023
In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapySara Corvigno, Sunil Badal, Meredith L Spradlin, et al.
Ebiomedicine|August 20, 2015
Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall SurvivalAlessandra Ferrajoli, Cristina Ivan, Maria Ciccone, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
Blood|July 12, 2019
Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemiaBrian Giacopelli, Qiuhong Zhao, Amy S Ruppert, et al.
JAMA Oncology|June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 TrialNitin Jain, Michael Keating, Philip Thompson, et al.
The Journal of Clinical Investigation|August 3, 2016
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsPartow Kebriaei, Harjeet Singh, M Helen Huls, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
Leukemia|May 19, 2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsNitin Jain, Philip Thompson, Jan Burger, et al.
Archives of Suicide Research : Official Journal of the International Academy for Suicide Research|June 26, 2026
Evaluation of the Overwatch Project for Active-Duty Servicemembers: Suicide Prevention with a Peer-Based Firearms Lethal Means Safety Training ApproachElisa Borah, Joseph C Geraci, Chris M Paine, et al.
NPJ Precision Oncology|November 4, 2023
In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapySara Corvigno, Sunil Badal, Meredith L Spradlin, et al.
Ebiomedicine|August 20, 2015
Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall SurvivalAlessandra Ferrajoli, Cristina Ivan, Maria Ciccone, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
Blood|July 12, 2019
Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemiaBrian Giacopelli, Qiuhong Zhao, Amy S Ruppert, et al.
JAMA Oncology|June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 TrialNitin Jain, Michael Keating, Philip Thompson, et al.
The Journal of Clinical Investigation|August 3, 2016
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsPartow Kebriaei, Harjeet Singh, M Helen Huls, et al.
Pageof 19